s0122158
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.400
- DNA_REPAIR+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- INFLAMMATORY_RESPONSE+0.300
- MITOTIC_SPINDLE+0.300
- MYC_TARGETS_V2+0.300
- PANCREAS_BETA_CELLS+0.300
Top 10 suppressed
- NOTCH_SIGNALING-0.400
- BILE_ACID_METABOLISM-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ADIPOGENESIS-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- ESTROGEN_RESPONSE_LATE-0.200
- KRAS_SIGNALING_DN-0.200
- APICAL_SURFACE-0.100
- HEDGEHOG_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934852 | — | — | 0.848 |
| 2 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.842 |
| 3 | BS_4QW2S1Q8 | high-grade glioma | — | 0.830 |
| 4 | 38e8a5f6-9edf-49bb-ab00-912a58fa363f | — | — | 0.818 |
| 5 | fca4c327-dfab-4455-84a8-f890a7326132 | — | — | 0.817 |
| 6 | TCGA-BT-A20X-01A-11R-A16R-07 | — | — | 0.813 |
| 7 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.812 |
| 8 | s0112234 | — | — | 0.811 |
| 9 | TCGA-IQ-A61E-01A-22R-A30B-07 | — | — | 0.810 |
| 10 | 040cf8cf-7b9d-4873-a51d-ba13bba4201a | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |